Active Ingredient(s): Tezepelumab-ekko
FDA Approved: * December 17, 2021
Pharm Company: * ASTRAZENECA AB
Category: Asthma

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tezspire Overview

Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma.[4][5] It blocks thymic stromal lymphopoietin (TSLP),[2] an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.[6] It was approved for medical use in the United States in December 2021.[2][3] Contents 1 Medical uses 2 Re...

Read more Tezspire Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tezepelumab

Recent Tezspire Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Solution: 210mg/1.91ml(110mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tezspire: (2 results)

Sorted by National Drug Code
  • 55513-100 Tezspire 210 mg/1.9ml Subcutaneous Injection, Solution by Amgen, Inc
  • 55513-112 Tezspire 210 mg/1.9ml Subcutaneous Injection, Solution by Amgen, Inc

Other drugs which contain Tezepelumab-ekko or a similar ingredient: (1 result)